Palatin 10-K: Going-Concern Warning Despite Narrowed Loss and $13.2M Collaboration Revenue
PTN sits 69% above its 52-week low of $5.61.
Summary
Palatin's annual report confirms a going-concern warning with only $7.5M in cash, while disclosing 8.76M shares of potential dilution from outstanding warrants and options.
Key Events · Earnings and Guidance · PTN
-
Going-Concern Warning
KPMG's audit report includes an explanatory paragraph for going-concern uncertainty. Management states substantial doubt exists about the company's ability to continue as a going concern for one year from the filing date.
-
Cash Runway Through H2 2026
Cash and cash equivalents of $7.5M as of June 30, 2026, are expected to fund operations only through the second half of calendar 2026 without additional financing.
-
Massive Potential Dilution
8,763,962 shares underlie outstanding convertible preferred stock, options, RSUs, and warrants — nearly 5x the 1,779,275 shares outstanding. This includes 2.77M Series K warrants at $8.13 and 2.77M Series J warrants at $6.50.
-
Collaboration Revenue
FY26 revenue of $13.2M came entirely from the Boehringer Ingelheim ($9.4M) and Altanispac ($3.8M) agreements. No product revenue is expected until a candidate receives regulatory approval.
Analysis · PTN · Life Sciences
Palatin's FY26 10-K confirms a going-concern warning from its auditor, KPMG, with only $7.5M in cash against a $8.4M net loss. The company's survival depends on raising additional capital, yet it has no committed financing. The filing also reveals massive potential dilution: 8.76M shares underlying outstanding warrants, options, and preferred stock — nearly 5x the 1.78M shares currently outstanding. While the Boehringer Ingelheim and Altanispac deals brought in $13.2M in collaboration revenue, the company's cash runway extends only through the second half of calendar 2026.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 42.1% of the 323 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTN was trading at $9.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17M. The 52-week trading range was $5.61 to $31.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.